Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Flagship Ventures Fund IV General Partner LLC (CIK 1508051) reported $584.9M across 5 reported positions in its SEC 13F filing for 2016-06-30. Largest positions: MCRB ($368.4M, 62.99%), EDIT ($120.9M, 20.67%), SYRS ($87.2M, 14.92%), TTOO ($5.9M, 1.00%), SESN ($2.5M, 0.42%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | MCRB | SERES THERAPEUTICS INC | $368.4M | 62.99% | 12.7M | Trimmed |
| 2 | EDIT | EDITAS MEDICINE INC | $120.9M | 20.67% | 5.0M | New |
| 3 | SYRS | SYROS PHARMACEUTICALS INC | $87.2M | 14.92% | 4.8M | New |
| 4 | TTOO | T2 BIOSYSTEMS INC | $5.9M | 1.00% | 741,755 | Hold |
| 5 | SESN | ELEVEN BIOTHERAPEUTICS INC | $2.5M | 0.42% | 1.5M | Hold |
Source: SEC Form 13F filings · as of 2016-06-30